SGLT2 inhibitors decrease overhydration and proteasuria in patients with chronic kidney disease: a longitudinal observational study

Author:

Schork Anja,Eberbach Marie-Luise,Bohnert Bernhard N.,Wörn Matthias,Heister David J.,Eisinger Felix,Vogel Elisabeth,Heyne Nils,Birkenfeld Andreas L.,Artunc Ferruh

Abstract

Introduction: SGLT2 inhibitors are used to reduce the risk of progression of chronic kidney disease (CKD). In patients with type 2 diabetes, they have been found to reduce extracellular volume. Given the high prevalence of extracellular volume expansion and overhydration in CKD, we investigated whether SGLT2 inhibitors might correct these disturbances in CKD patients. Methods: CKD patients who started treatment with an SGLT2 inhibitor were investigated in this prospective observational study for 6 months. Body composition and fluid status were measured by bioimpedance spectroscopy. In addition, spot urine samples were analyzed for albuminuria, glucosuria and urinary aprotinin-sensitive serine protease activity. Results: 42 patients (29 % with diabetic/hypertensive CKD, 31 % with IgA nephropathy; 88 % dapagliflozin 10 mg, 10 % dapagliflozin 5 mg, 2 % empagliflozin 20 mg; median eGFR 46 mL/min/1.73m² and albuminuria 1911 mg/g creatinine) participated in the study. Median glucosuria increased to 14 (10-19) g/g creatinine. At baseline, patients displayed overhydration (OH) with + 0.4 (-0.2 – 2.2) L/1.73m² which decreased by 0.5 (0.1 – 1.2) L/1.73m² after 6 months. Decrease of OH correlated with higher OH at BL, decrease of albuminuria, glucosuria and urinary aprotinin-sensitive protease activity. Adipose tissue mass was not significantly reduced after 6 months. Conclusion: SGLT2 inhibitors reduce overhydration in patients with CKD, which is pronounced in the presence of high albuminuria, glucosuria and urinary aprotinin-sensitive protease activity.

Publisher

S. Karger AG

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3